SCHEDULE: Commodore Capital Discloses Stake in Definium Therapeutics

Commodore Capital LP and its affiliates have reported a beneficial ownership of 1.8% of Definium Therapeutics, Inc. common shares, acquiring them through a combination of direct holdings and pre-funded warrants.

Summary

• Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, have filed a Schedule 13G, indicating beneficial ownership of Definium Therapeutics, Inc. common shares.
• The total beneficial ownership reported is 2,410,000 shares, representing 1.8% of the class of securities.
• This ownership includes 2,000,000 directly held shares and 410,000 shares issuable upon exercise of pre-funded warrants.
• The filing date for this amendment is June 30, 2026, with the report being signed on August 14, 2026.
• Commodore Capital LP acts as the investment manager for Commodore Capital Master LP.
• Michael Kramarz and Robert Egen Atkinson are managing partners of Commodore Capital LP and exercise investment discretion over the reported securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not dominant ownership stake by a known investment firm. The filing itself is procedural and doesn't contain operational or financial performance data, making a definitive sentiment difficult.

Positives

• The filing indicates a significant investment firm, Commodore Capital, has taken a notable stake in Definium Therapeutics.
• The acquisition of shares, including through pre-funded warrants, suggests a strategic interest in the company's future.

Negatives

• The ownership stake of 1.8% is relatively small, suggesting Commodore Capital is not seeking control but rather a passive investment.
• The filing does not provide any information on the financial performance or operational status of Definium Therapeutics, limiting insight into the investment's underlying rationale.

Risks

• The value of the investment is subject to the performance and market valuation of Definium Therapeutics.
• Changes in investment strategy by Commodore Capital could lead to the sale of shares, potentially impacting the stock price.

Future Outlook

The filing itself is a disclosure of ownership and does not contain forward-looking statements or guidance regarding Definium Therapeutics' future performance. The future outlook for the investment depends on the company's operational and financial results.

Management Comments

• Commodore Capital LP may be deemed to beneficially own an aggregate of 2,410,000 shares of Common Shares.
• Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities.

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by an investment firm like Commodore Capital is a common event in the biotechnology or healthcare sector, often signaling a strategic investment or a response to recent company developments. The specific context for Definium Therapeutics would require further analysis of the company's business and recent news.

Comparison to Industry Standards

• As a Schedule 13G filing, it represents a passive investment stake. Industry standards for passive stakes by investment firms vary widely depending on the firm's strategy and the size of the company. A 1.8% stake is typical for a significant but non-controlling position in a publicly traded company.
• The use of pre-funded warrants is a common mechanism in the investment landscape, particularly for institutional investors looking to acquire shares at a potentially favorable effective price while deferring immediate capital outlay compared to purchasing shares directly on the open market.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest, potentially influencing stock price and liquidity. However, the 1.8% stake is unlikely to lead to immediate control changes.
• Management of Definium Therapeutics: Awareness of significant passive ownership by an investment firm can influence strategic decision-making.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Monitor Definium Therapeutics' financial reports and operational updates for performance indicators.
• Observe any future filings by Commodore Capital for changes in their ownership stake.
• Analyze Definium Therapeutics' strategic initiatives and market position.

Key Dates

Keywords

Commodore Capital, Definium Therapeutics, Schedule 13G, Beneficial Ownership, Pre-funded Warrants, Investment Management, Common Shares